Inquiry Basket
Catalog | Product Name | CAS Number |
---|---|---|
BADC-01404 | PNU159682-EDA | 2255344-14-8 |
PNU159682-EDA is a drug-linker conjugate for ADC by using PNU159682 (a potent DNA topoisomerase II inhibitor), linked via EDA. | Inquiry | |
BADC-01406 | Ozogamicin | 400046-53-9 |
Ozogamicin is a drug-linker conjugates for ADC. Ozogamicin can be used in the synthesis of gemtuzumab ozogamicin and inotuzumab ozogamicin. | Inquiry | |
BADC-01407 | SPDB-DM1 | |
SPDB-DM1 is a mertansine-linked drug that is a cytotoxic agent. It is used as the cytotoxic component in antibody-drug conjugates. | Inquiry | |
BADC-01408 | DBM(C6)-VC-PAB-MMAE | 1644228-55-6 |
DBM(C6)-VC-PAB-MMAE is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01409 | Mal-PEG4-VC-PAB-EDA-PNU159682 | 2571582-15-3 |
Mal-PEG4-VC-PAB-EDA-PNU159682 is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01410 | MA-PEG4-VC-PAB-MMAE | 2851435-57-7 |
MA-PEG4-VC-PAB-MMAE is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01411 | MPB-VC-PAB-DM1 | |
MPB-VC-PAB-DM1 is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01412 | MA-PEG4-VC-PAB-DMAE-Doxorubicin | |
MA-PEG4-VC-PAB-DMAE-Doxorubicin is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01413 | DBM-MMAE | 1912408-87-7 |
DBM-MMAE is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01414 | CL2A-Chimmitecan | |
CL2A-Chimmitecan is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01415 | DM21 | 2243689-80-5 |
DM21 is a profound biomedical product employed for combating cancer and inflammation. It showcases its remarkable prowess in thwarting malignant tumor progression and alleviating inflammatory responses through precise modulation of distinctive molecular cascades. Vigorously investigated and validated, DM21 emerges as an inhibitory force impeding tumor proliferation whilst mitigating inflammatory disorders, thus proffering a wide array of promising therapeutic avenues in the realm of diverse cancer categories and inflammatory afflictions. | Inquiry | |
BADC-01416 | C-lock-PEG4-MMAE | |
C-lock-PEG4-MMAE is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01417 | MC-VC-PAB-DMEA-PNU159682 | 1178887-17-6 |
MC-VC-PAB-DMEA-PNU159682 is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01418 | C-lock-G5-Dxd | |
C-lock-G5-Dxd is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01419 | C-lock-GGFG-Dxd | |
C-lock-GGFG-Dxd is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01420 | C-lock-GGFG-Exatecan | |
C-lock-GGFG-Exatecan is a thiol-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01421 | DBCO-PEG4-GGFG-DMEA-PNU159682 | |
DBCO-PEG4-GGFG-DMEA-PNU159682 is a click-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01422 | DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) | |
DBCO-PEG4-VC-PAB-DMEA-((S)-Seco-Duocarmycin SA) is a click-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01423 | NH2-PEG3-DMEA-PNU159682 | |
NH2-PEG3-DMEA-PNU159682 is a sortase-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
BADC-01424 | NH2-VC-PAB-DMEA-PNU159682 | 2227350-96-9 |
NH2-VC-PAB-DMEA-PNU159682 is a sortase-reactive drug-linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry |